No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
FGF R Agonists are a class of oncology drugs that act on the fibroblast growth factor receptor (FGF R). These drugs are used to treat a variety of cancers, including breast, lung, and colorectal cancer. FGF R Agonists work by activating the FGF R, which in turn stimulates the growth of new blood vessels and increases the delivery of oxygen and nutrients to the tumor. This helps to reduce the size of the tumor and improve the patient's prognosis.
FGF R Agonists are typically administered intravenously or subcutaneously, and can be used in combination with other cancer treatments such as chemotherapy and radiation therapy. They are also used to treat certain types of anemia and other blood disorders.
The FGF R Agonist market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more
